Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7529 - 7536 of 12085 results

MintzTech Connect Industry News - December 2016
December 15, 2016| Article| Viewpoint

MintzTech Innovator Profile: T-REX
December 15, 2016| Article| Viewpoint

Supreme Court to Hear Patent Venue Case
December 15, 2016| Blog| Viewpoint

President Obama Signs 21st Century Cures Act; Creates Accelerated Approval Pathway for Regenerative Medicine
December 15, 2016| Blog| Viewpoint

Once Meek Agency Flexes its Muscles, But Likely to Face Pushback Under Trump
December 15, 2016| News

FDA Increases Transparency of Adverse Event Data for Cosmetics and Foods
December 15, 2016| Blog| Viewpoint

The Use of Experts in International Arbitration: Tribunal-Appointed Experts
December 14, 2016| Blog| Viewpoint

The Use of Experts in International Arbitration: Preparing the Expert Witness to Give Oral Testimony
December 14, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
